Edition:
United Kingdom

Intersect ENT Inc (XENT.OQ)

XENT.OQ on NASDAQ Stock Exchange Global Market

34.35USD
12 Jan 2018
Change (% chg)

-- (--)
Prev Close
$34.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
61,810
52-wk High
$35.25
52-wk Low
$11.75

Latest Key Developments (Source: Significant Developments)

Intersect ENT Reports Preliminary Q4 And Year 2017 Revenue
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Intersect ENT Inc ::INTERSECT ENT REPORTS PRELIMINARY Q4 AND YEAR 2017 REVENUE.SEES FY 2018 REVENUE $111 MILLION TO $116 MILLION.SEES Q1 2018 REVENUE $23.2 MILLION TO $23.7 MILLION.SEES FY 2017 REVENUE $96.1 MILLION TO $96.3 MILLION.SEES FY 2018 REVENUE UP 15 TO 20 PERCENT.SEES Q4 2017 REVENUE $29.3 MILLION TO $29.5 MILLION.- CO CONTINUES TO EXPECT TO LAUNCH SINUVA COMMERCIALLY IN Q2 OF 2018.Q4 EARNINGS PER SHARE VIEW $-0.17, REVENUE VIEW $27.7 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $113.8 MILLION -- THOMSON REUTERS I/B/E/S.FY2017 REVENUE VIEW $94.5 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

‍James Flynn​ reports 5.92 pct passive stake in Intersect ENT
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Intersect Ent Inc ::‍James Flynn​ reports 5.92 percent passive stake in Intersect ENT as of Nov 6 - SEC filing.  Full Article

FDA performs pre-approval inspection of Intersect ENT's menlo park facility
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Intersect ENT Inc :FDA performs pre-approval inspection of Intersect ENT's menlo park facility.Intersect ENT Inc - ‍FDA has set a pdufa target action date of January 7, 2018​.Intersect ENT Inc - ‍at conclusion of inspection, FDA issued a form 483 with four inspectional observations​.Intersect ENT Inc - does not expect inspectional observations to impact timeline for a decision from FDA on approval of sinuva implant​.  Full Article

Intersect ENT Inc reports Q3 revenue $22.3 million
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Intersect ENT Inc :Intersect ENT Inc reports third quarter 2017 results.Q3 revenue $22.3 million versus I/B/E/S view $21.5 million.Sees q4 2017 revenue $27.3 million to $27.8 million.Intersect ENT Inc - ‍outlook for 2017 gross margin continues to be about 84%​.Intersect ENT Inc - ‍for full year 2017 expects revenue in range of $94.1-$94.6 million​.  Full Article

Intersect Q2 loss per share $0.21
Tuesday, 2 Aug 2016 

Intersect ENT Inc : Q2 loss per share $0.21 . Q2 revenue $19.3 million versus I/B/E/S view $18.8 million . Intersect ENT reports second quarter 2016 results . Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S . Sees Q3 2016 revenue about $17.8 million . Fy2016 revenue view $78.3 million, q3 revenue view $18.4 million -- Thomson Reuters I/B/E/S .Expects full year revenue at low end of previous guidance range of $78 million-$80 million.  Full Article

Intersect ENT announces FDA submission of NOVA
Monday, 1 Aug 2016 

Intersect ENT Inc :Intersect ENT announces FDA submission of NOVA bioabsorbable steroid releasing implant for patients with chronic sinus disease.  Full Article

BRIEF-Intersect ENT prelim Q2 revenue $19.3 mln
Monday, 18 Jul 2016 

Corrects third bullet to preliminary revenue, not reported revenue.Intersect Ent Inc : Says company's Chief Commercial Officer Chas McKhann is departing for personal reasons . Announces preliminary Q2 revenue and business update .Q2 preliminary revenue $19.3 million versus I/B/E/S view$18.8 million.  Full Article

Intersect ENT Inc reaffirms FY 2016 revenue guidance
Thursday, 5 May 2016 

Intersect ENT Inc:Continues to project revenue for FY 2016 in the range of $78-$80 million.  Full Article

BRIEF-Intersect ENT Reports Preliminary Q4 And Year 2017 Revenue

* - CO CONTINUES TO EXPECT TO LAUNCH SINUVA COMMERCIALLY IN Q2 OF 2018